SCHEMBL27010386

SCHEMBL27010386

CC(C)C1(C)CCCN1Cc1ccc(S(=O)(=O)N2CCOCC2)cc1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.57
POLB P06746 2/20 0.50
TSHR P16473 2/20 0.49
LMNA P02545 2/20 0.46
GAA P10253 2/20 0.46
KDM4E B2RXH2 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
KCNH2 Q12809 1/20 0.43
HRH3 Q9Y5N1 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
ALOX15 P16050 1/20 0.43
MAPK1 P28482 1/20 0.43
PTGDR2 Q9Y5Y4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27010256 0.97 ALDH1A1 (0.56) ALDH1A1POLBTSHRLMNAGAA
SCHEMBL24315682 0.87 L3MBTL1 (0.48) ALDH1A1POLBLMNASMN1; SMN2MAPK1
SCHEMBL26620383 0.86 ALDH1A1 (0.55) ALDH1A1POLBTSHRLMNAGAA
SCHEMBL24316172 0.84 L3MBTL1 (0.47) ALDH1A1POLBTSHRLMNASMN1; SMN2
SCHEMBL24315834 0.82 POLB (0.57) ALDH1A1POLBTSHRLMNAGAA
SCHEMBL24317831 0.82 PTGDR2 (0.43) ALDH1A1POLBTSHRGAASMN1; SMN2
SCHEMBL27010255 0.80 ALDH1A1 (0.55) ALDH1A1POLBTSHRLMNAGAA
SCHEMBL24315790 0.79 PTGDR2 (0.43) ALDH1A1POLBTSHRGAASMN1; SMN2
SCHEMBL27010252 0.79 TSHR (0.60) ALDH1A1POLBTSHRLMNAGAA
SCHEMBL27010324 0.78 ALDH1A1 (0.61) ALDH1A1POLBTSHRLMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C 4 Therapeutics, Inc. (US) 2024-01-18 US disclosed
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C 4 Therapeutics, Inc. (US) 2024-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY NFATC1, CTSS, MMP12 ALDH1A1 2267/4885POLB 469/4885TSHR 2445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.